Gut Microbiota Elicits a Protective Immune Response against Malaria Transmission

Bahtiyar Yilmaz,1 Silvia Portugal,2 Tuan M. Tran,2 Raffaella Gozzelino,1 Susana Ramos,1 Joana Gomes,1,3 Ana Regalado,1 Peter J. Cowan,4,6 Anthony J.F. d’Apice,4,6 Anita S. Chong,6 Ogobara K. Doumbo,7 Boubacar Traore,7 Peter D. Crompton,2 Henrique Silveira,3 and Miguel P. Soares1,*

1Instituto Gulbenkian de Ciência, Rua da Quinta Grande, 6, 2780-156 Oeiras, Portugal
2Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II, Room 125, 12441 Parklawn Drive, Rockville, MD 20852-8180, USA
3Centro de Malaria e Outras Doencas Tropicais, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Rua da Junqueira, 100, 1349-008 Lisboa, Portugal
4Immunology Research Centre, St. Vincent’s Hospital, Fitzroy, Melbourne, VIC 3065, Australia
5Department of Medicine, University of Melbourne, Parkville, VIC 2900, Australia
6Section of Transplantation, Department of Surgery, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
7Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, 1805 Bamako, Mali
*Correspondence: mpssoares@igc.gulbenkian.pt
http://dx.doi.org/10.1016/j.cell.2014.10.053
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

SUMMARY

Glycosylation processes are under high natural selection pressure, presumably because these can modulate resistance to infection. Here, we asked whether inactivation of the UDP-galactose:β-galactoside-α1-3-galactosyltransferase (α1,3GT) gene, which ablated the expression of the Galα1-3Galβ1-4GlcNAc-R (α-gal) glycan and allowed for the production of anti-α-gal antibodies (Abs) in humans, confers protection against Plasmodium spp. infection, the causative agent of malaria and a major driving force in human evolution. We demonstrate that both Plasmodium spp. and the human gut pathobiont E. coli O86:B7 express α-gal and that anti-α-gal Abs are associated with protection against malaria transmission in humans as well as in α1,3GT-deficient mice, which produce protective anti-α-gal Abs when colonized by E. coli O86:B7. Anti-α-gal Abs target Plasmodium sporozoites for complement-mediated cytotoxicity in the skin, immediately after inoculation by Anopheles mosquitoes. Vaccination against α-gal confers sterile protection against malaria in mice, suggesting that a similar approach may reduce malaria transmission in humans.

INTRODUCTION

Humans have relatively high levels of circulating antibodies (Abs) recognizing xeno-glycans expressed by pathogens (Oye-laran et al., 2009). As for other antigens, xeno-glycans cannot be targeted by the immune system when also expressed as self-glycans. This limitation can be bypassed by natural selection of mutations that inactivate the expression of self-glycans (Bishop and Gagneux, 2007). Presumably, natural selection of such loss-of-function mutations tailored the human anti-glycan immune repertoire through evolution (Bishop and Gagneux, 2007). This notion is supported by the inactivation of the cytidine monophosphate-N-acetylneuraminic acid hydroxylase-like (CMAH) gene in humans, which suppressed the expression of N-glycolyneuraminic acid (Neu5Gc) (Hayakawa et al., 2001) and allowed for immune reactivity against Neu5Gc (Tangvornnutakah et al., 2003). In a similar manner, inactivation of the α1,3GT gene, which suppressed the expression of the Galα1-3Galβ1-4GlcNAc-R (α-gal) carbohydrate in ancestral anthropoid primates that gave rise to humans (Galili and Swanson, 1991), also allowed for immune reactivity against α-gal (Galili et al., 1984). While it has been argued that this evolutionary process is driven to a large extent by the acquisition of immune-resistance to pathogens expressing such glycans (Bishop and Gagneux, 2007; Cywes-Bentley et al., 2013), this was never tested experimentally.

Humans do not express α-gal and up to 1%–5% of the repertoire of circulating immunoglobulin M (IgM) and immunoglobulin G (IgG) in healthy adults is directed against this glycan (Macher and Galili, 2008). Production of α-gal-specific Abs is thought to be driven by exposure to bacterial components of the microbiota expressing α-gal (Macher and Galili, 2008), including specific members of the Klebsiella spp., Serratia spp., and Escherichia coli spp. (Galili et al., 1988). Expression of α-gal by these Enterobacteriaceae is associated with the bacterial capsule and cell wall glycoproteins, as well as with lipopolysaccharide (LPS) (Galili et al., 1988). Gut colonization by the human pathobiont E. coli O86:B7 (Pal et al., 1969) recapitulates the etiology of anti-α-gal Ab production in mice (Posekany et al., 2002) and in primates (Mañez et al., 2001), as well as the production of Abs directed against the α-gal-related anti-B blood group glycan in chickens.
Malaria is transmitted to humans by the inoculation of Plasmodium sporozoites via the bite of female Anopheles (A.) mosquitoes (Ménard et al., 2013). While transmission may be rather efficient, only a fraction of the inoculated parasites manage to progress toward the establishment of infection (Rickman et al., 1990; Sauerwein et al., 2011; Verhage et al., 2009), hinting at a natural mechanism of protection that presumably targets the initial phases of the Plasmodium lifecycle. Here, we demonstrate that production of anti-α-gal Abs in response to the gut E. coli O86:B7 pathobiont contributes critically to this natural defense mechanism, reducing malaria transmission by A. mosquitoes.

RESULTS

Plasmodium spp. Express the α-Gal Glycan

The α-gal glycan was detected on the surface of Plasmodium sporozoites, as assessed by immunofluorescence for the human pathogen Plasmodium falciparum 3D7, as well as for the transgenic GFP-expressing strains of the rodent pathogens Plasmodium berghei ANKA (PbB) or Plasmodium yoelii 17XLN (Py), using the lectin Bandeiraea (Griffonia) simplicifolia-1 isoelectrin IB₄ (BSI-B₄) (Galili et al., 1985) or an anti-α-gal monoclonal antibody (M86 mAb) (Galili et al., 1998) (Figure 1A; Figures S1A and S1B available online). Specificity of α-gal detection was confirmed by its enzymatic removal using α-galactosidase (E).

Figure 1. Detection of α-Gal in Plasmodium Sporozoites

(A) Composite images of GFP/actin (green), α-gal (red; white arrows), and DNA (blue) in Plasmodium sporozoites. (B) Same staining as (A), after removal of α-gal by α-galactosidase. Images are representative of 2–3 independent experiments. Scale bar, 5 μm. (C) Detection of α-gal in PbAα-gal-GFP sporozoites by flow cytometry, representative of three independent experiments. (D) Detection of α-gal in proteins extracted from salivary glands of noninfected (NI), P. falciparum 3D7 (Pf), PbAα-gal-GFP (Pb), or P. yoelii 17XLN (Py)-infected A. mosquitoes. Histone H3 (Hist3) and GFP were detected as loading controls. When indicated, α-gal was digested using α-galactosidase (E). (E and F) Detection of α-gal (E) and CSP (F) in PbAα-gal-GFP sporozoites treated or not with phospholipase C (+PLC). Control is not stained. Data representative of 2–4 independent experiments. See also Figure S1.
(Figure 1D) and confirmed by enzymatic removal of α-gal (Figure 1D). Residual levels of α-gal were detected in the salivary glands of noninfected mosquitoes, suggesting that this glycan may be generated, at least partially, by A. mosquitoes (Figure 1D).

Expression of α-gal by Pba sporozoites was reduced by ~4-fold when the glycosylphosphatidylinositol (GPI) anchor was cleaved by phospholipase C (PLC), as assessed by flow cytometry (Figure 1E). In contrast, GPI cleavage failed to reduce the expression of circumsporozoite protein (CSP), the main protein expressed at the surface of Plasmodium sporozoites (Figure 1F). This suggests that α-gal is bound to GPI-anchored surface proteins, including or not CSP, which despite being GPI-anchored (Moran and Caras, 1994) is resistant to PLC cleavage (Kimmel et al., 2003) (Figure 1F).

α-Gal-Specific IgM Abs Are Associated with Protection from P. falciparum Infection in Humans

We investigated whether a correlation exists between the levels of anti-α-gal Abs in healthy uninfected children and adults before the malaria season (n = 330 for IgG; n = 229 for IgM) and subsequent risk of P. falciparum infection (determined by biweekly PCR analysis of fingerprick blood samples) and febrile malaria (determined by weekly physical examination), during the ensuing 6-month malaria season in a cohort study in Mali, where this season is predictable and intense (Tran et al., 2014). In children <2 years, the average level of anti-α-gal IgM Abs was 33.4 µg/ml (95% confidence interval [CI]: 18.4–48.3 µg/ml) (Figure 2A), similar to that reported in children with no history of malaria exposure (Avila et al., 1992; Doenz et al., 2000; Galli et al., 1984; Parker et al., 1999). However, anti-α-gal IgM Abs increased with age, reaching an average of 123.03 µg/ml (95% CI: 79.3–166.7 µg/ml) in adults — more than twice the level reported in adults with no malaria exposure, i.e., 51.6 µg/ml (95% CI: 14.9–88.3 µg/ml) (Figure 2A) (Avila et al., 1992; Doenz et al., 2000; Galli et al., 1984; Parker et al., 1999). The average level of anti-α-gal IgG Abs in children >4 years of age who had no P. falciparum infections detected during the 6-month malaria season (n = 13) was higher than those who became infected (n = 141) (Figure 2B). This suggests that there is a positive correlation between the levels of anti-α-gal IgM Abs and incidence of P. falciparum infection.

The average level of anti-α-gal IgG Abs in children <2 years was 1.46 µg/ml (95% CI: 0.22–0.69 µg/ml) and increased in adults to 3.66 µg/ml (95% CI: 3.04–4.28 µg/ml) (Figure 2C). In contrast to IgM, the levels of circulating α-gal-specific IgG were similar between malaria-exposed and nonexposed adults, suggesting that P. falciparum infection fails to drive an IgG response directed against α-gal (Figure 2D). This also suggests that there is no correlation between anti-α-gal IgG Abs and incidence of P. falciparum infection. Time-to-event analysis did not show a correlation between α-gal-specific IgG Abs and incidence of P. falciparum infection.

**Gut Colonization by E. coli O86:B7 Elicits a Protective α-Gal-Specific IgM Ab Response against Malaria Transmission**

To test whether anti-α-gal IgM Abs are protective against malaria transmission, we took advantage of “human-like” a1,3Gt−/− deficient mice. Unlike humans, wild-type mice have a functional a1,3Gt gene and express α-gal on secreted and cell-surface glycoproteins, suppressing the development of anti-α-gal immunity (Yang et al., 1998). Deletion of a1,3Gt gene eliminates α-gal (Tearle et al., 1996), allowing for anti-α-gal Ab production in a1,3Gt−/− mice (Chiang et al., 2000; Tearle et al., 1996; Yang et al., 1984; Parker et al., 1999). However, anti-α-gal IgM Abs were increased with age, reaching an average of 123.03 µg/ml (95% CI: 79.3–166.7 µg/ml) in adults — more than twice the level reported in adults with no malaria exposure, i.e., 51.6 µg/ml (95% CI: 14.9–88.3 µg/ml) (Figure 2A) (Avila et al., 1992; Doenz et al., 2000; Galli et al., 1984; Parker et al., 1999). The average level of anti-α-gal IgG Abs in children >4 years of age who had no P. falciparum infections detected during the 6-month malaria season (n = 13) was higher than those who became infected (n = 141) (Figure 2B). This suggests that there is a positive correlation between the levels of anti-α-gal IgM Abs and incidence of P. falciparum infection.

The average level of anti-α-gal IgG Abs in children <2 years was 1.46 µg/ml (95% CI: 0.22–0.69 µg/ml) and increased in adults to 3.66 µg/ml (95% CI: 3.04–4.28 µg/ml) (Figure 2C). In contrast to IgM, the levels of circulating α-gal-specific IgG were similar between malaria-exposed and nonexposed adults, suggesting that P. falciparum infection fails to drive an IgG response directed against α-gal (Figure 2D). This also suggests that there is no correlation between anti-α-gal IgG Abs and incidence of P. falciparum infection. Time-to-event analysis did not show a correlation between α-gal-specific IgG Abs and incidence of P. falciparum infection.
et al., 1998). However, α1,3Gt⁻/⁻ mice are known to produce only residual levels of circulating anti-α-gal Abs when maintained under specific pathogen-free (SPF) conditions (Chiang et al., 2000). Production of anti-α-gal Abs can be enhanced upon enteric exposure to *E. coli* O86:B7 (Posekany et al., 2002). We confirmed that *E. coli* O86:B7 expresses high levels of α-gal (Yi et al., 2006), which is not the case for the *E. coli* K12 strain (Figures 3A and 3B). Colonization of α1,3Gt⁻/⁻ mice by *E. coli* O86:B7 after antibiotic treatment (streptomycin sulfate; 5 g/l in drinking water for 7 days prior to colonization) increased the levels of circulating anti-α-gal IgM Abs from 1.4 μg/ml (95% CI: 1.1–1.8 μg/ml) to 162.9 μg/ml (95% CI: 95.89–230.1 μg/ml) before and after colonization, respectively (Figure 3C). Levels of anti-α-gal IgM Abs in colonized α1,3Gt⁻/⁻ mice were in the range of adult individuals from a malaria endemic region (Figure 2A). In contrast, the levels of circulating anti-α-gal IgG2 Abs remained at residual levels, i.e., <1 μg/ml (Figure S2A), again in the range of adult individuals from a malaria endemic region (Muramatsu et al., 2000). Gut colonization of *E. coli* K12 did not induce the production of circulating anti-α-gal Abs when maintained under SPF conditions (Chiang et al., 2006), which is not the case for the *E. coli* K12, or colonized with O86:B7 strains (2–3 experiments; n = 12). (D) Incidence of blood stage of *Plasmodium* infection (%) in mice colonized or not by *E. coli* K12, or colonized with O86:B7 strains (2–3 experiments; n = 12). (E) Incidence of blood stage of *Plasmodium* infection (%) in α1,3Gt⁻/⁻, α1,3Gt⁻/⁻ and α1,3Gt⁻/⁻/S⁻/⁻ mice colonized as in (C) and exposed to *Pb* AEEF1a-GFP-infected A. stephensi mosquitoes (1–2 experiments; n = 4–10). (F) Anti-α-gal IgM Abs were measured in GF α1,3Gt⁻/⁻ mice not colonized (GF), colonized with *E. coli* K12, or colonized with O86:B7 strains (2–3 experiments; n = 12). (G) Incidence of blood stage of *Plasmodium* infection (%) in mice colonized as in (F) and exposed to *Pb* AEEF1a-GFP-infected A. stephensi mosquitoes (four experiments; n = 9–13). Mean (red bars). See also Figure S2.

Figure 3. Gut Colonization by *E. coli* Expressing α-gal Protects against *Plasmodium* Infection

(A and B) Detection of α-gal in *E. coli* strains by (A) flow cytometry and (B) immunofluorescence. Representative of 2–3 independent experiments. Composite images in (B), i.e., α-gal (green) and DNA (blue) at 100 x magnification. Scale bar, 10 μm.

(C) α1,3Gt⁻/⁻ mice maintained under SPF were treated with streptomycin for 7 days. (D) Anti-α-gal IgM Abs levels were measured in α1,3Gt⁻/⁻ mice not colonized (SPF), colonized with *E. coli* K12, or colonized with O86:B7 strains (2–3 experiments; n = 12). (D) Incidence of blood stage of *Plasmodium* infection (%) in mice colonized as in (C) and exposed to *Pb* AEEF1a-GFP-infected A. stephensi mosquitoes (four experiments; n = 17–34).

(E) Incidence of blood stage of *Plasmodium* infection (%) in α1,3Gt⁻/⁻ JHT⁻/⁻, α1,3Gt⁻/⁻ Aid⁻/⁻, and α1,3Gt⁻/⁻ JHT⁻/⁻/S⁻/⁻ mice colonized as in (C) and exposed to *Pb* AEEF1a-GFP-infected A. stephensi mosquitoes (1–2 experiments; n = 4–10).

(F) Anti-α-gal IgM Abs were measured in GF α1,3Gt⁻/⁻ mice not colonized (GF), colonized with *E. coli* K12, or colonized with O86:B7 strains (2–3 experiments; n = 12). (G) Incidence of blood stage of *Plasmodium* infection (%) in mice colonized as in (F) and exposed to *Pb* AEEF1a-GFP-infected A. stephensi mosquitoes (four experiments; n = 9–13). Mean (red bars). See also Figure S2.
suggesting that these are natural Abs (Figure 3F). The production of anti-α-gal IgM Abs in GF α1,3Gt⁺⁻ mice being driven by expression of these glycans in food components is possible, but this has not been tested. GF α1,3Gt⁺⁻ mice did not produce anti-α-gal IgG Abs (Figure S2C). Susceptibility to Pba transmission by infected A. mosquitoes was similar in SPF versus GF α1,3Gt⁺⁻ mice (Figures 3D and 3G). When GF α1,3Gt⁺⁻ mice were monocolonized by E. coli O86:B7, the levels of circulating anti-α-gal IgM Abs increased to 96.62 µg/ml (95% CI: 79.32–133.9 µg/ml) (Figure 4), which is in the range in which adult individuals from a malaria endemic region (Figure 2A), without concomitant induction of anti-α-gal IgG Abs (Figure S2C). Monocolonization by E. coli O86:B7, but not by E. coli K12, protected α1,3Gt⁺⁻ mice from Pba transmission by A. mosquitoes (Figure 3F). This suggests that gut colonization by a specific pathobiont expressing α-gal recapitulates to a large extent the normal etiology of the human anti-α-gal Ab response (Figure 2) and immunization against α-Gal Protects from Plasmodium Transmission

Immunization of α1,3Gt⁺⁻ mice against α-gal, using rabbit RBC membranes (rRBCM) expressing high levels of α-gal or synthetic α-gal conjugated to BSA (α-gal-BSA) elicited the production of circulating anti-α-gal IgM and IgG Abs (Figure 4A). Control α1,3Gt⁺⁺ mice failed to produce anti-α-gal Abs (Chiang et al., 2000; Tearle et al., 1996; Yang et al., 1998) (Figure S3A). Circulating anti-α-gal immunoglobulin A (IgA) and immunoglobulin E (IgE) Abs were undetectable in control or immunized α1,3Gt⁺⁻ and α1,3Gt⁺⁺ mice (data not shown). The concentration of anti-α-gal IgM Abs in the plasma of immunized α1,3Gt⁺⁻ mice was in the range of adult individuals from malaria endemic regions (Figure 2A). Circulating anti-α-gal IgG Abs in immunized...
versus control nonimmunized A. stephensi mosquitoes, as well as from PBA transmission by A. gambiae mosquitoes (Figure 4D) versus control nonimmunized A. stephensi mosquitoes nor against PBA transmission by A. gambiae mosquitoes (Figure S3D) versus naive a,3Gt+/−/− mice.

Immunization a,3Gt+/−/− mice were protected from artificial transmission of PBA sporozoites via intradermal inoculation versus control nonimmunized a,3Gt+/−/− mice (Figure 4E) or control immunized or nonimmunized a,3Gt+/+/+ mice (Figure S3E). Protection was no longer observed when sporozoites were inoculated intravenously (Figures 4E and S3E). This suggests that the protective effect of α-gal immunization is exerted in the dermis, presumably via an anti-α-gal Ab driven mechanism that is no longer effective once sporozoites reach the blood.

PBA transmission was associated with accumulation of Plasmodium 18S rRNA at the site of inoculation, as quantified in the ear pinna by qRT-PCR (Figure 4F). The relative amount of Plasmodium 18S rRNA was similar in immunized versus control nonimmunized a,3Gt+/−/− mice (Figure 4F) or control immunized or nonimmunized a,3Gt+/+/+ mice (Figure S3F). Immunized a,3Gt+/−/− mice did not accumulate Plasmodium 18S rRNA in the liver, when compared to control nonimmunized a,3Gt+/−/− mice (Figure 4F) or control nonimmunized or immunized a,3Gt+/+/+ mice (Figure S3F). This suggests that α-gal immunization arrests the transit of inoculated sporozoites from the skin into the liver, without interfering with sporozoite inoculation by A. mosquitoes.

TLR9 Agonist Adjuvant Enhances the Protective Effect of α-Gal Immunization

Immunization a,3Gt+/−/− mice with rRBCM emulsified in complete Freund’s adjuvant (CFA), supplemented with toll-like receptor 9 agonist CpG, enhanced anti-α-gal IgG2b and IgG3 Ab response by 2- to 3-fold (Figure 4G) versus immunization without adjuvant (Figure 4A). This was associated with 88% reduction in the relative risk of transmission of PBA infection by A. mosquitoes (95% CI: 0.032–0.452) versus 61% reduction upon immunization without adjuvant (95% CI: 0.209–0.726) (Figures 4B and 4H). This protective effect was not observed in control a,3Gt+/+/+ mice (Figures S3G and S3H).

Parasitemias were similar in immunized a,3Gt+/−/− mice not protected from PBA infection versus control nonimmunized a,3Gt+/−/− mice as well as control nonimmunized or immunized a,3Gt+/+/+ mice (data not shown). Moreover, when infected, all mice succumbed to experimental cerebral malaria. This suggests that while protective against malaria transmission, α-gal immunization is not protective against the development of severe disease if Plasmodium manages to establish infection. In keeping with this notion, when inoculated with PBA-infected RBC, immunized a,3Gt+/−/− mice developed similar levels of parasitemia and disease severity, as compared to control nonimmunized a,3Gt+/−/− mice as well as to control nonimmunized or immunized a,3Gt+/+/+ mice (Figure S4A).

We tested further whether the protective effect conferred by α-gal immunization is associated with sterile protection, i.e., inability of Plasmodium to establish blood stage of infection. Passive transfer of RBCs harvested from protected immunized a,3Gt+/−/− mice at day 8–9 post-PBA transmission by A. mosquitoes failed to transmit disease to naive a,3Gt+/−/− mice (Figure S4B). In contrast, passive transfer of RBC harvested from nonprotected immunized a,3Gt+/−/− mice, readily transmitted disease to naive a,3Gt+/−/− mice (Figure S4B). This demonstrates that the protective effect of immunization against α-gal is associated with sterile protection against malaria.

Anti-α-Gal IgM and IgG Abs Produced in Response to α-Gal Immunization Confer Protection against Malaria Transmission

We asked whether the protective effect of α-gal immunization is mediated by anti-α-gal IgM and/or IgG Abs. Immunized a,3Gt+/−/− /JtyT+/− mice failed to produce anti-α-gal IgM or IgG Abs versus naive a,3Gt+/−/− /JtyT+/− mice or immunized a,3Gt+/−/− mice (Figure 5A). Moreover, immunized a,3Gt+/−/− /JtyT+/− mice were not protected against PBA transmission by A. mosquitoes versus control nonimmunized a,3Gt+/−/− /JtyT+/− mice (Figure 5B). This shows that the protective effect of α-gal immunization is mediated via a B cell-dependent mechanism.

Immunization a,3Gt+/−/− /Aid+/− mice failed to induce the production of anti-α-gal IgG, but not IgM Abs, versus naive a,3Gt+/−/− /Aid+/− or immunized a,3Gt+/−/− mice (Figure 5A). Immunized a,3Gt+/−/− /Aid+/− mice were nevertheless protected against PBA transmission by A. mosquitoes versus nonimmunized a,3Gt+/−/− /Aid+/− mice (Figure 5B). This confirms that anti-α-gal IgM Abs can confer protection against malaria transmission (Figure 2B) and that the protective effect of α-gal-specific IgM Abs does not require somatic hypermutation.

Immunization a,3Gt+/−/− /μS+/− mice failed to induce anti-α-gal IgM Abs, without interfering with anti-α-gal IgG Ab response versus naive a,3Gt+/−/− /μS+/− mice or immunized a,3Gt+/−/− mice (Figure 5A). Immunized a,3Gt+/−/− /μS+/− mice were nevertheless protected from PBA transmission by A. mosquitoes versus control naive a,3Gt+/−/− /μS+/− mice (Figure 5B). Immunized a,3Gt+/−/− /μS+/− mice did not produce circulating anti-α-gal IgA or IgE Abs (data not shown) and a putative protective effect for these Ig isotypes was excluded. This demonstrates that anti-α-gal IgG Abs produced in response to immunization confer protection against malaria transmission.

Immunization a,3Gt+/−/− /Tcrb−/− mice lacking mature αβ T cells (Mombaerts et al., 1992) compromised anti-α-gal IgM and IgG response versus control immunized a,3Gt+/−/− mice (Figure 5A). Immunized a,3Gt+/−/− /Tcrb−/− mice were not protected from PBA transmission by A. mosquitoes versus control naive a,3Gt+/−/− /Tcrb−/− mice (Figure 5B). This shows that anti-α-gal Abs produced in response to immunization are T cell-dependent (Cretin et al., 2002) and so is their protective effect.

1282 Cell 159, 1277–1289, December 4, 2014 ©2014 The Authors
Specificity of anti-\(\alpha\) mAbs recognize specifically and only the \(Pb\) by ELISA using binding to \(\alpha\) malaria. This was not the case for levels of parasitemia and succumbed to experimental cerebral mice, not protected from \(Pb\)ogenesis of experimental cerebral malaria (Belnoue et al., 2002).

Passive transfer of anti-\(\alpha\)-gal IgM to naive \(\alpha,3Gt^{-/−}\) mice conferred protection against \(Pb\) transmission by \(A\). mosquitoes (Figure 5C). This was also the case for passive transfer of anti-\(\alpha\)-gal Abs from specific IgG subclasses, namely, IgG2b and IgG3 (Figure 5C), but not IgG1 or IgG2a (Figure 5C). Relative binding to \(\alpha\)-gal was similar for all mAbs tested, as assessed by ELISA using \(\alpha\)-gal-BSA as a solid-phase antigen (Figure S6A) or by immunofluorescence using \(Pb\) sporozoites (Figure S6B). Specificity of anti-\(\alpha\)-gal binding to \(Pb\) sporozoites was assessed by enzymatic removal of \(\alpha\)-gal, confirming that these mAbs recognize specifically and only the \(\alpha\)-gal glycan on the surface of \(Pb\) sporozoites (Figure S6C). IgG2a, IgG2b, and IgG3 mAbs are class-switched mutants derived from the original anti-\(\alpha\)-gal IgG1 clone and as such have similar affinities for \(\alpha\)-gal (Ding et al., 2008). These data reveal that while IgM anti-\(\alpha\)-gal Abs are sufficient per se to confer protection against malaria transmission, this protective effect can be enhanced when specific subclasses anti-\(\alpha\)-gal IgG Abs are present at sufficient high levels.

Once bound to the surface of \(Pb\) sporozoites, anti-\(\alpha\)-gal IgM, IgG2b, and IgG3 mAbs activated the classical pathway of complement, as assessed by C3 deposition (Figure 5D). Anti-\(\alpha\)-gal IgG1 or IgG2a mAbs failed to activate complement (data not shown), and complement activation was also not observed in the absence of anti-\(\alpha\)-gal Abs (Figures 5D and S7), showing that the alternative and lectin pathways of complement are not activated by \(Pb\) sporozoites.

We then asked whether the protective effect exerted by anti-\(\alpha\)-gal Abs is mediated via a mechanism involving the activation of the complement cascade (Figure 5D) (Ding et al., 2008; Miyatake et al., 1998). Passive transfer of anti-\(\alpha\)-gal IgM Abs or anti-\(\alpha\)-gal IgG2b mAb to \(\alpha,3Gt^{-/−}\) mice, which lack C3 and cannot activate the complement cascade, failed to confer protection against \(Pb\) transmission versus control \(\alpha,3Gt^{-/−}\) mice (Figure 5E). Passive transfer of anti-\(\alpha\)-gal IgG3 mAb to \(\alpha,3Gt^{-/−}\) mice conferred residual but significant protection versus control \(\alpha,3Gt^{-/−}\) mice (Figure 5E). This
suggests that the protective effect exerted by anti-α-gal IgM and IgG2b Abs acts via a mechanism that is strictly complement dependent, whereas the protective effect of anti-α-gal IgG3 Abs is partially but probably not strictly dependent on complement activation. Infection incidence was similar in control α1,3Gt-/-C3-/- versus α1,3Gt-/-C3+/- mice (Figures 5C and 5E).

Complement activation generates C3a and C5a chemoattractants that promote IgG-dependent polymorphonuclear (PMN) cell cytotoxicity (Ding et al., 2008; Nimmerjahn and Ravetch, 2008; Yin et al., 2004). Therefore, we asked whether the protective effect of anti-α-gal IgG3 Abs is partially but probably not strictly dependent on complement activation. Infection incidence was similar in control α1,3Gt-/-C3-/- versus α1,3Gt-/-C3+/- mice (Figures 5C and 5E).

Anti-α-gal Abs Are Cytotoxic to Plasmodium Sporozoites

Complement activation by anti-α-gal IgM, IgG2b, or IgG3 Abs was cytotoxic to P. berghei sporozoites in vitro, as assessed by sporozoite GFP expression (Figure 6A). Anti-α-gal IgG1 and IgG2a Abs, which did not activate complement when bound to Plasmodium sporozoites (data not shown), were not cytotoxic (Figure 6A).

The cytotoxic effect of anti-α-gal IgM, IgG2b, and IgG3 was similar when using mouse (Figure 6A) or rabbit (Figure S7A) complement but was strictly dependent on the presence of complement (Figure S7B). A similar cytotoxic effect was observed when quantifying viable "crescent-shaped" sporozoites (Figure S7C), an independent readout for sporozoite viability (Hegge et al., 2010). Isotype-matched control anti-dinitrophenyl (DNP) Abs were not cytotoxic to P. berghei sporozoites in vitro (Figures 6A and S7A–S7C).

Anti-α-gal Abs Inhibit Hepatocyte Invasion by Plasmodium Sporozoites

We asked whether anti-α-gal Abs inhibit hepatocyte transmigration (wounding) and/or hepatocyte invasion by Plasmodium sporozoites (Mota et al., 2001). Complement activation by anti-α-gal IgM, IgG2b, and IgG3 Abs inhibited hepatocyte transmigration (Figure 6B) and invasion (Figure 6C), as assessed in vitro for P. berghei sporozoites. This inhibitory effect was not observed when using anti-α-gal IgG1 or IgG2a Abs or isotype/subclass-matched control anti-DNP Abs (Figures 6B and 6C).

We then assessed whether anti-α-gal Abs inhibit the development of exoeukaryotic forms (EEF) of Plasmodium. Complement activation by anti-α-gal IgM, IgG2b, and IgG3 Abs reduced the number of EEF (Figure 7A), as well as the average EEF size (Figures 7B and 7C) formed in vitro by P. berghei sporozoites. Anti-α-gal IgG1 Abs did not show this inhibitory effect, while anti-α-gal IgG2a Abs did not reduce the number of EEF (Figure 7A) but had a residual inhibitory effect on EEF size (Figures 7B and

Figure 6. Protective Effect of Anti-α-gal Abs against Hepatocyte Infection

(A) Mean percentage (%) of viable GFP+ P. berghei sporozoites ± STD (3–4 experiments) after exposure in vitro to anti-α-gal or control anti-DNP mAbs in the presence of mouse complement. (B and C) Mean percentage (%) of HepG2 cells (B) wounded (Dextran-Red+) or (C) invaded (GFP+) by P. berghei sporozoites treated as in (A) ± SD (six experiments).

Figure 7. Anti-α-gal Abs Inhibit Exoeukaryotic Forms of Plasmodium

(A) Percentages (+SD) of EEF in mouse (Figure 7A) or rabbit (Figure S7A) complement. (B and C) Mean percentage (%) of HepG2 cells (B) wounded (Dextran-Red+) or (C) invaded (GFP+) by P. berghei sporozoites treated as in (A) ± SD (six experiments).
levels of cytotoxic anti-α-Plasmodium modulate EEF numbers (Figure 7A) or average size (Figures 7B and 7C). Isotype/subclass-matched control anti-DNP Abs did not

**DISCUSSION**

When inoculated in humans through the bite of an A. mosquito, Plasmodium sporozoites are confronted with relatively high levels of cytotoxic anti-α-gal IgM Abs (Figure 2A). That these Abs are protective against malaria transmission is supported by three independent lines of evidence. First, individuals from a malaria endemic region that show evidence of decreased P. falciparum infection risk have higher levels of circulating α-gal-specific IgM Abs, as compared to individuals who are susceptible to P. falciparum infection (Figure 2B). Second, when present at levels similar to those observed in individuals from a malaria endemic region—in α1,3Gt−/− mice colonized by human gut pathobiont E. coli O86:B7 expressing α-gal (Figure 3) or in immunized α1,3Gt−/− mice (Figures 4A and 4B)—anti-α-gal IgM Abs confer protection against malaria transmission. Third, passive transfer of anti-α-gal IgM Abs is sufficient per se to protect α1,3Gt−/− mice from malaria transmission (Figure 5C).

The protective effect exerted by anti-α-gal IgM Abs should be relevant to understand why malaria incidence is higher in children versus adults from malaria endemic regions (Modiano et al., 1996). Relative absence of these antibodies in children under the age of 2–3 years should favor malaria transmission, as compared to adults that have higher levels of circulating anti-α-gal IgM Abs (Figure 2A). This relative absence of anti-α-gal IgM in children may be explained by the (1) kinetics of establishment of an adult-like gut microbiota (Ringel-Kulka et al., 2013), (2) requirement of environmental and dietary exposure in the establishment of an adult-like gut microbiota, and/or (3) the kinetics of the establishment of adult-like B cell repertoire, including anti-α-gal B cells.

The protective effect exerted by anti-α-gal IgM Abs might also contribute to explain why only a small fraction of Plasmodium sporozoites inoculated by mosquitoes manage to progress toward the establishment of infection in humans. This is true even when Plasmodium sporozoites are inoculated under controlled experimental conditions in adults (Rickman et al., 1990; Sauerwein et al., 2011; Verhage et al., 2005). Presumably, when present at sufficient high levels in adults, circulating anti-α-gal IgM Abs prevent the large majority of Plasmodium sporozoites from establishing a successful infection. However, infection is established if as few as a couple of Plasmodium sporozoites manage to escape this natural mechanism of protection.

Whether α-gal detected at the surface of Plasmodium sporozoites (Figure 1) is produced by Plasmodium and/or by the mosquito is not clear. The salivary glands of noninfected mosquitoes express low levels of α-gal, as detected by western blot (Figure 1) and immunostaining (data not shown). Plasmodium sporozoites are masked by mosquito laminin (Warburg et al., 2007), an evolutionary conserved glycoprotein that in other species contains α-gal (Takahashi et al., 2014). It is possible therefore that anti-α-gal Abs recognize laminin or another mosquito-derived protein expressing α-gal, masking Plasmodium sporozoites (Warburg et al., 2007).
It is now well established that specific components of the gut microbiota can modulate immunity and resistance to infection (Belkaid and Hand, 2014; Honda and Litman, 2012). In support of this notion, resistance to viral and bacterial (Fagundes et al., 2012) infections is impaired in GF mice (Dolowy and Muldoon, 1964) or mice subjected to antibiotic-driven dysbiosis (Ichinoh et al., 2011). We reasoned that xeno-glycans expressed by specific components of the gut microbiota might trigger a protective immune response against pathogens expressing the same xeno-glycans. We show that this is the case for α-gal, a xeno-glycan expressed by the human gut pathobiont E. coli O86:B7, as well as by Plasmodium spp. (Figures 1, 3A, and 3B). When colonized by E. coli O86:B7, α1,3Gtα-gal mice produce an anti-α-gal IgM Ab response (Figures 3C and 3F) that confer protection against Plasmodium infection (Figures 3D, 3E, 3G, and 5C) via a lytic mechanism mediated by complement activation (Figures 5E and 6A). It is worth noticing that in a similar manner to other microbiota-driven resistance mechanisms, the protective effect exerted by E. coli O86:B7 acts at the level of a tissue barrier, i.e., the skin, to prevent Plasmodium transmission (Figures 4E and 4F).

Levels of circulating anti-α-gal IgG Abs in individuals from a malaria endemic region (Figure 2C), as well as in α1,3Gtα-gal mice colonized with E. coli O86:B7 (Figures S2A and S2C), are ~30-fold and ~40 to 70-fold, respectively, lower than levels of IgM anti-α-gal Abs. This may explain why basal levels of anti-α-gal IgG Abs in individuals from a malaria endemic region are not associated with decreased risk of P. falciparum infection (Figure 2D). This also suggests that P. falciparum infection fails to induce class switch of the anti-α-gal Ig Ab response in those individuals. It is possible therefore that P. falciparum represses Ig class-switch recombination, explaining the residual levels of circulating anti-α-gal IgG Abs (Figure 2C).

While anti-α-gal Abs can provide sterile protection against malaria in mice (Figures 5B, 5C, and S4B), this is not commonly observed in malaria endemic regions in which adult individuals have circulating anti-α-gal IgM Abs, possibly because the levels of these Abs are below a threshold level required to provide sterile protection (Figure 2). However, we show that this natural mechanism of protection can be enhanced via immunization using adjuvants that favor the production of T cell-dependent complement fixing anti-α-gal IgG Abs (Figures 4G and 4H). Moreover, when coupled to Plasmodium antigens, this approach should enhance the immunogenicity of such antigens (Benatil et al., 2005) and boost the protective efficacy of candidate malaria vaccines based on such antigens (Olotu et al., 2013). This approach should be useful in preventing not only individual infections but also disease transmission given the protective effect of anti-α-gal Abs.

It is possible that the protective effect of “attenuated” sporozoite vaccine trials against malaria (Seder et al., 2013) is driven to some extent by an anti-α-gal Ab response, given the expression of α-gal by Plasmodium falciparum sporozoites (Figure 1). Whether a correlation can be established between the effectiveness of such candidate vaccines and a putative anti-α-gal IgG Ab response has not been established but may be useful to consider as a retrospective analyzes.

As a final note, we predict that in a similar manner to anti-α-gal Abs other anti-glycan Abs may confer protection against malaria as well as other vector-borne protozoan parasites (Huflejt et al., 2009; Lacroix-Desmazes et al., 1995; Nagele et al., 2013). Moreover, anti-α-gal Abs may also target other vector-borne protozoan parasites expressing α-gal, such as Leishmania spp. and Trypanosoma spp., the causative agents of Leishmaniasis and Trypanosomiasis, respectively (Avila et al., 1989). As such, vaccination approaches similar to the one proposed here for malaria may be considered against these diseases as well.

**EXPERIMENTAL PROCEDURES**

**Cohort Study**

For detailed analysis, see the Extended Experimental Procedures.

**Immunization against α-Gal**

Eight- to ten-week-old mice received 3 × 10⁶ rabbit rRBCM equivalents (100 µl; PBS; intraperitoneal [i.p.]). Adjuvants are described in the Extended Experimental Procedures. Mouse serum was collected 2 weeks after last immunization, and circulating anti-α-gal Abs were quantified by ELISA. See the Extended Experimental Procedures for details on anti-α-gal ELISA.

**Passive Transfer of Anti-α-Gal mAbs**

α1,3Gtα-gal mice received anti-α-gal IgG1, IgG2a, IgG2b, and IgG3 mAbs (Ding et al., 2008; Yin et al., 2004) (150 µg; 100 µl per mouse) or polyclonal IgG (150 µg; 300–400 µl per mouse) via a single intravenous (i.v.) injection 24 hr prior to mosquito exposure.

**Plasmodium Strains**

Transgenic P. berghei ANKA (PbA) strains expressing GFP under the eef1α promoter, i.e., PbA<sup>EF1α-GFP</sup> (259c11; MR4; MRA-865) (Franke-Fayard et al., 2004), or under the hsp70 promoter (Ishino et al., 2006), i.e., PbA<sup>AHsp70-GFP</sup> (kindly provided by Robert Menard, Institut Pasteur), transgenic P. yoelli 17XNL strain expressing GFP under the PbA eef1α promoter (MR4; MRA-1871; kindly provided by Robert Menard, Institut Pasteur) (Weiss et al., 1989). For sporozoite production, see the Extended Experimental Procedures.

**Plasmodium Transmission**

A. stephensi or gambiae mosquitoes were allowed to feed on anesthetized mice (i.p.; 125 mg/kg ketamine; 12.5 mg/kg xylazine) placed on a warming tray. Two mosquitoes were allowed to probe and feed independently (90–100 s) on restricted to the edge of the mouse ear (10–12/3–4 mm) and dissected thereafter for confirmation of sporozoites in salivary glands. If negative, infection was repeated.

**Sporozoites Inoculation**

PbA<sup>EF1α-GFP</sup> sporozoites were inoculated (i.d.) in the ear pinna (750 sporozoites in 20–30 µl; 1% BSA in PBS) or i.v. in the retro-orbital vein (150 sporozoites in 50 µl; 1% BSA in PBS) using a microsyringe (Nanofil 100 µl; 33G beveled needle; World Precision Instruments).

**Detection of α-Gal in Plasmodium Sporozoites**

Sporozoites were stained with Alexa Fluor 647-conjugated BSI-IB4 or Alexa Fluor 647-conjugated anti-α-gal mAbs and detected by confocal microscope or flow cytometer. For detection of α-gal in PbA<sup>AHsp70-GFP</sup> by western blotting, see the Extended Experimental Procedures. Green coffee bean α-galactosidase (30–200 µl; 5 U/ml; 60–90 min; 25°C; Sigma Chemical) was used to hydrolyze terminal α-galactosyl moieties from glycolipids and glycoproteins (Luo et al., 1999).

**Statistical Analysis**

All tests (except human cohort studies) were performed using the GraphPad Prism (v. 6.0) (GraphPad Software). Human analyses were performed in R (v. 3.0.2). Detailed analyses are described in the Extended Experimental Procedures.
Mice
Experiments in mice were performed in accordance with protocols approved by the Ethics Committee of the Instituto Gulbenkian de Ciência and the Portuguese National Entity (DGAV-Direção Geral de Alimentação e Veterinária). Experiments in mice were performed in accordance with the Portuguese (Decreto-Lei no. 113/2013) and European (directive 2010/63/EU) legislation related to housing, husbandry, and animal welfare. C57BL/6 J+/Tcr−/− (Gu et al., 1993), Tcr−/− (Mombaerts et al., 1992), Ad−/− (Muramatsu et al., 2003), aS−/− (Ehrenstein et al., 1998), and C3−/− (Circolo et al., 1999) mice were crossed with C57BL/6 α,bGal−/− mice (Shinkel et al., 1997; Tearie et al., 1996). For the details on genotyping, see the Extended Experimental Procedures.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and seven figures and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2014.10.053.

AUTHOR CONTRIBUTIONS
B.Y. contributed to study design, performed, and/or contributed critically to all experiments, analyzed data, and contributed to writing of the manuscript. In some experiments, B.Y. was assisted by S.R., S.P., T.M.T., and P.D.C. designed, performed, and analyzed the human studies. R.G. performed the western blot experiments. H.S. supervised J.G. in the establishment and main-

ACKNOWLEDGMENTS
The authors thank the Inflammation Group (IGC) for insightful discussions and review of the manuscript, Sofia Rebelo and Silvia Cardoso for mouse breeding and genotyping, Pedro Almada and Nuno Pimpão Martins (IGC FACIL-

REFERENCES
Avila, J.L., Rojas, M., and Galili, U. (1989). Immunogenetic Gal alpha 1—-3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J. Immunol. 142, 2828–2834.
Avila, J.L., Rojas, M., and Velazquez-Avila, G. (1992). Characterization of a nat-

present at high titers in chronic Trypanosoma cruzi infection. Am. J. Trop. Med. Hyg. 47, 413–421.
Belkaid, Y., and Hand, T.W. (2014). Role of the microbiota in immunity and inflam-

Belnoue, E., Kayibanda, M., Vigario, A.M., Deschemin, J.C., van Rooijen, N., Viguier, M., Snouou, G., and Rénaix, L. (2002). On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J. Immunol. 169, 6369–6375.
Benatuil, L., Kaye, J., Rich, R.F., Fishman, J.A., Green, W.R., and Iacomini, J. (2005). The influence of natural antibody specificity on antigen immunogene-

Bishop, J.R., and Gagneux, P. (2007). Evolution of carbohydrate antigens—mi-

Chen, L., Zhang, Z., and Sendo, F. (2000). Neutrophils play a critical role in the pathogenesis of experimental cerebral malaria. Clin. Exp. Immunol. 120, 125–133.
Chiang, T.R., Fanget, L., Gregory, R., Tang, Y., Ardiel, D.L., Gao, L., Mescher, C., Kozikowski, A.P., Buelow, R., and Vuist, W.M. (2000). Anti-gal antibodies in humans and 1,3galactosyltransferase knock-out mice. Transplantation 69, 2593–2600.
Cretin, N., Bracy, J., Hanson, K., and Iacomini, J. (2002). The role of T cell help in the production of antibodies specific for Gal alpha 1-3Gal. J. Immunol. 168, 1479–1483.
Cywes-Bentley, C., Skurnik, D., Zaidi, T., Roux, D., Deoliveira, R.B., Garrett, W.S., Lu, X., O’Malley, J., Kinzel, K., Zaidi, T., et al. (2013). Antibody to a conserved antigenic target is protective against diverse prokaryotic and eu-

Doenz, U., Nydegger, U.E., Kueng, A., Carrel, T., and Mohacsy, P. (2000). Anti-Galalpha1-3GalIgM/IgG antibody levels in infants: do they have a clinical relevance in pediatric xenotransplantation? J. Heart Lung Transplant. 19, 1108–1113.
Dolowy, W.C., and Muldoon, R.L. (1964). Studies of germfree animals. I. Response of mice to infection with influenza A virus. Proc. Soc. Exp. Biol. Med. 116, 365–371.
Ehrenstein, M.R., O’Keefe, T.L., Davies, S.L., and Neuberger, M.S. (1998). Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc. Natl. Acad. Sci. USA 95, 10089–10093.
Fagundes, C.T., Amaral, F.A., Vieira, A.T., Soares, A.C., Pinho, V., Nicoli, J.R., Vieira, L.O., Teixeira, M.M., and Souza, D.G. (2012). Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J. Immunol. 188, 1411–1420.
Franke-Fayard, B., Trueman, H., Ramesar, J., Mendoza, J., van der Keur, M., van der Linden, R., Sindén, R.E., Waters, A.P., and Janse, C.J. (2004). A Plas-

Galili, U., and Swanson, K. (1991). Gene sequences suggest inactivation of alpha 1,3galactosyltransferase in cataractines after the divergence of apes from monkeys. Proc. Natl. Acad. Sci. USA 88, 7401–7404.
Galili, U., LaTempel, H., and Radic, M.Z. (1998). A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation 65, 1129–1132.
Galili, U., Rachmilewitz, E.A., Peleg, A., and Flechner, I. (1984). A unique nat-

Cell 159, 1277–1289, December 4, 2014 ©2014 The Authors
Galili, U., Mandrell, R.E., Hamadeh, R.M., Shohet, S.B., and Griffiss, J.M. (1988). Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 56, 1730–1737.

Gu, H., Zhou, Y.R., and Rajewsky, K. (1993). Independent control of immunoglobin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73, 1155–1164.

Hayakawa, T., Satta, Y., Gagneux, P., Varki, A., and Takahata, N. (2001). Altered inactivation of the human CMP- N-acetylenuraminic acid hydroxylase gene. Proc. Natl. Acad. Sci. USA 98, 11399–11404.

Hegge, S., Kudryashev, M., Barniol, L., and Frischknecht, F. (2010). Key factors regulating Plasmodium berghei sporozoite survival and transformation revealed by an automated visual assay. FASEB journal 24, 5003–5012.

Honda, K., and Littman, D.R. (2012). The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 30, 759–795.

Hufnfeld, M.E., Vuskovic, M., Vasiliiu, D., Xu, H., Obukhova, P., Shilova, N., Tuzikov, A., Galanina, O., Arun, B., Lu, K., and Bovin, N. (2009). Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol. Immunol. 46, 3037–3049.

Ichinohe, T., Pang, I.K., Kumamoto, Y., Peaper, D.R., Ho, J.H., Murray, T.S., and Iwasaki, A. (2011). Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. USA 108, 5354–5359.

Ishino, T., Orito, Y., Chinzai, Y., and Yuda, M. (2006). A calcium-dependent protein kinase regulates Plasmodium oocyste access to the midgut epithelial cell. Mol. Microbiol. 59, 1175–1184.

Kimmel, J., Ogun, S.A., de Macedo, C.S., Gerold, P., Vivas, L., Holder, A.A., Schwarz, R.T., and Azzouz, N. (2003). Glycosylphosphatidylinositol in murine malaria: Plasmodium yoelii yoelii. Biochimie 85, 473–481.

Lacroix-Desmazes, S., Mouton, L., Coutinho, A., and Kazatchkine, M.D. (1995). Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Eur. J. Immunol. 25, 2598–2604.

Luo, Y., Wen, J., Luo, C., Cummings, R.D., and Cooper, D.K. (1999). Pig xeno-geneic antigen modification with green coffee bean alpha-galactosidase. Xenotransplantation 6, 238–248.

Macher, B.A., and Galili, U. (2008). The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim. Biophys. Acta 1780, 75–88.

Mañéz, R., Blanco, F.J., Díaz, I., Centeno, A., Lopez-Pelaez, E., Hermida, M., Davies, H.F., and Katopodis, A. (2001). Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural alpha-galactosyl IgG antibodies. Xenotransplantation 8, 15–23.

Ménard, R., Tavares, J., Cockburn, I., Markus, M., Zavala, F., and Amino, R. (2013). Looking under the skin: the first steps in malarial infection and immunity. Nat. Rev. Microbiol. 11, 701–712.

Miyatake, T., Kato, K., Takigami, K., Koyamada, N., Hancock, W.W., Bazin, H., Muramatsu, M., Kimmel, J., Ogun, S.A., de Macedo, C.S., Gerold, P., Vivas, L., Holder, A.A., Schwarz, R.T., and Azzouz, N. (2003). Glycosylphosphatidylinositol in murine malaria: Plasmodium yoelii yoelii. Biochimie 85, 473–481.

Nagele, E.P., Han, M., Acharya, N.K., DeMarshall, C., Kociuk, M.C., and Nagele, R.G. (2013). Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS ONE 8, e60726.

Nimmerjahn, F., and Ravetch, J.V. (2008). Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47.

Okutsu, N., Fegan, G., Wambua, J., Nyangweso, G., Awuondo, K.O., Leach, A., Liewins, M., Leboilleux, D., Njoguna, P., Peshu, N., et al. (2013). Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368, 1111–1120.

Oyelaran, O., McShane, L.M., Dodd, L., and Gildersleeve, J.C. (2009). Profiling human serum antibodies with a carbohydrate antigen microarray. J. Proteome Res. 8, 4301–4310.

Pal, S.C., Rao, C.K., Kereselidze, T., Krishnaswami, A.K., Murty, D.K., Pandit, C.G., and Shrivastav, J.B. (1969). An extensive community outbreak of entero-pathogenic Escherichia coli O86:B7 gastroenteritis. Bull. World Health Organ. 41, 851–858.

Parker, W., Lin, S.S., Yu, P.B., Sood, A., Nakamura, Y.C., Song, A., Everett, M.L., and Platt, J.L. (1999). Naturally occurring anti-alpha-galactosyl antibodies: relationship to xenoreactive anti-alpha-galactosyl antibodies. Glycobiology 9, 865–873.

Porcherie, A., Mathieu, C., Peronet, R., Schneider, E., Claver, J., Commere, P.H., Kiefer-Biasizzo, H., Karasuyama, H., Milton, G., Dy, M., et al. (2011). Critical role of the neutrophil-associated high-affinity receptor for IgE in the pathogenesis of experimental cerebral malaria. J. Exp. Med. 208, 2225–2236.

Posekany, K.J., Pittman, H.K., Bradfield, J.F., Haisch, C.E., and Verbanac, K.M. (2002). Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria. Infect. Immun. 70, 6215–6222.

Rickman, L.S., Jones, T.R., Long, G.W., Paparello, S., Schneider, I., Paul, C.F., Beaudoin, R.L., and Hoffman, S.L. (1990). Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am. J. Trop. Med. Hyg. 43, 441–445.

Ringel-Kulka, T., Cheng, J., Ringel, Y., Salojärvi, J., Carroll, I., Palva, A., de Vos, W.M., and Satokari, R. (2013). Intestinal microbiota in healthy U.S. young children and adults—a high throughput microarray analysis. PLoS ONE 8, e63431.

Sauerwein, R.W., Roestenberg, M., and Moorthy, V.S. (2011). Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11, 57–64.

Seder, R.A., Chang, L.J., Enama, E.M., Zephir, K.L., Sarvar, U.N., Gordon, I.J., Holman, L.A., James, E.R., Billingsley, P.F., Gunasekera, A., et al. (2013). Study Team (2013). Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359–1365.

Springer, G.F., and Horton, R.E. (1969). Blood group isoantibody stimulation in man by feeding blood group-active bacteria. J. Clin. Invest. 48, 1280–1291.

Springer, G.F., Horton, R.E., and Forbes, M. (1959). [Origin of anti-human blood group B agglutinins in white Lebhorn chickens]. J. Exp. Med. 107, 221–244.

Sakai, A., and Suzuki, S. (2014). Laminin α1 and collagen α1(IV) chain are galactose-α1,3,1-galactosyl-bound allergens in beef. Allergy 69, 199–207.

Takeuchi, Y., Porter, C.D., Strahan, K.M., Preece, A.F., Gustafsson, K., Casset, F.L., Weiss, R.A., and Collins, M.K. (1996). Sensitization of cells and retrovirus to human serum by (alpha 1-3) galactosyltransferase. Nature 379, 85–88.
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., and Muchmore, E. (2003). Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. USA 100, 12045–12050.

Tearle, R.G., Tange, M.J., Zannettino, Z.L., Katerelos, M., Shinkel, T.A., Van Denderen, B.J., Lonie, A.J., Lyons, I., Nottle, M.B., Cox, T., et al. (1996). The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation 61, 13–19.

Tran, T.M., Ongoiba, A., Coursen, J., Crosnier, C., Diof, A., Huang, C.Y., Li, S., Doumbo, S., Doumtable, D., Kone, Y., et al. (2014). Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J. Infect. Dis. 209, 789–798.

Verhage, D.F., Telgt, D.S., Bousema, J.T., Hermsen, C.C., van Gemert, G.J., van der Meer, J.W., and Sauerwein, R.W. (2005). Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth. J. Med. 63, 52–58.

Warburg, A., Shtern, A., Cohen, N., and Dahan, N. (2007). Laminin and a Plasmodium ookinete surface protein inhibit melanotic encapsulation of Sephadex beads in the hemocoel of mosquitoes. Microbes Infect. 9, 192–199.

Weiss, W.R., Good, M.F., Hollingdale, M.R., Miller, L.H., and Berzofsky, J.A. (1989). Genetic control of immunity to Plasmodium yoelii sporozoites. J. Immunol. 143, 4263–4266.

Yang, Y.G., deGoma, E., Ohdan, H., Bracy, J.L., Xu, Y., Lacomini, J., Thall, A.D., and Sykes, M. (1998). Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism. J. Exp. Med. 187, 1335–1342.

Yi, W., Bystricky, P., Yao, Q., Guo, H., Zhu, L., Li, H., Shen, J., Li, M., Ganguly, S., Bush, C.A., and Wang, P.G. (2006). Two different O-polysaccharides from Escherichia coli O86 are produced by different polymerization of the same O-repeating unit. Carbohydr. Res. 341, 100–108.

Yin, D., Zeng, H., Ma, L., Shen, J., Xu, H., Byrne, G.W., and Chong, A.S. (2004). Cutting edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts. J. Immunol. 172, 7235–7238.